Nasal ventilation in acute exacerbations of chronic obstructive pulmonary disease: effect of ventilator mode on arterial blood gas tensions

D J Meecham Jones, E A Paul, C Grahame-Clarke, J A Wedzicha

Abstract

Background — There are no controlled trials of the use of different modes of nasal intermittent positive pressure ventilation (NIPPV) in patients with exacerbations of chronic obstructive pulmonary disease (COPD). This study describes the effect on blood gas tensions of four different modes of nasal ventilation.

Methods — Twelve patients with acute exacerbations of COPD were studied (mean (SD) FEV1 0.59 (0.13) l, PaO2 (air) 5.10 (1.12) kPa, PaCO2 9.28 (1.97) kPa, pH 7.32 (0.03)). Each patient underwent four one-hour periods of nasal ventilation in randomised order: (a) inspiratory pressure support 18 cm H2O; (b) pressure support 18 cm H2O + positive end expiratory pressure (PEEP) 6 cm H2O (IPAP + EPAP); (c) continuous positive airway pressure (CPAP) 8 cm H2O; and (d) volume cycled NIPPV. Arterial blood samples were obtained before each period of ventilation and at one hour.

Results — Pressure support, CPAP, and volume cycled NIPPV all produced significant improvements in PaO2; there was no difference between these three modes. The change in PaO2 with IPAP + EPAP did not reach statistical significance. None of the modes produced significant changes in mean PaCO2; patients with higher baseline levels tended to show a rise in PaCO2 whereas those with lower baseline levels tended to show a fall.

Conclusions — Although PaO2 improved in all patients there are differences in efficacy between the modes, while the changes in PaCO2 were variable. The addition of EPAP conferred no advantage in terms of blood gas tensions.

Acute hypercapnic respiratory failure due to chronic obstructive pulmonary disease (COPD) is associated with a high mortality rate.1 Nasal intermittent positive pressure ventilation (NIPPV) has been used in acute exacerbations of COPD with benefits including improvement in blood gases and reduced mortality compared with conventional therapy.2 3 5

We have shown no difference in efficacy between pressure and volume cycled nasal ventilator systems in patients with stable chronic respiratory failure,4 but there have been no studies comparing different ventilator systems in acute on chronic respiratory failure. We have investigated the effectiveness of two different systems of nasal ventilation and the effect of adding positive end expiratory pressure in patients with acute exacerbations of COPD.

EQUIPMENT

Two different nasal ventilator systems were used in this study, with ventilation through the Respironics nasal mask: (a) the BiPAP ventilatory support system (Respironics Inc, Murrysville, Pennsylvania, USA) is a pressure cycled ventilator adjusted to provide independent levels of inspiratory and expiratory positive airway pressures (IPAP and EPAP respectively), pressure support ventilation (IPAP), or CPAP; and (b) the Brompton PAC nasal ventilator (PneuPAC UK, Luton, UK) is a time and volume cycled system which functions in assist/control mode.

Spirometry was measured using a hand-held spirometer (Micro Medical Ltd, Rochester, Kent, UK). Arterial blood gases were measured with a CIBA Corning 278 blood gas system (Corning Medical, Medfield, Massachusetts, USA).

Table 1 Physiological data on admission

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age (years)</th>
<th>FEV1 (l)</th>
<th>FVC (l)</th>
<th>pH</th>
<th>PaO2 (air) (kPa)</th>
<th>PaCO2 (air) (kPa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>72</td>
<td>0.39</td>
<td>1.44</td>
<td>7.36</td>
<td>5.15</td>
<td>7.77</td>
</tr>
<tr>
<td>2</td>
<td>62</td>
<td>0.86</td>
<td>1.61</td>
<td>7.32</td>
<td>4.41</td>
<td>8.69</td>
</tr>
<tr>
<td>3</td>
<td>72</td>
<td>0.73</td>
<td>1.48</td>
<td>7.35</td>
<td>7.12</td>
<td>7.26</td>
</tr>
<tr>
<td>4</td>
<td>68</td>
<td>0.43</td>
<td>1.17</td>
<td>7.29</td>
<td>3.94</td>
<td>13.12</td>
</tr>
<tr>
<td>5</td>
<td>76</td>
<td>0.64</td>
<td>1.76</td>
<td>7.30</td>
<td>6.89</td>
<td>9.11</td>
</tr>
<tr>
<td>6</td>
<td>49</td>
<td>0.48</td>
<td>1.01</td>
<td>7.34</td>
<td>5.84</td>
<td>8.14</td>
</tr>
<tr>
<td>7</td>
<td>70</td>
<td>0.56</td>
<td>1.61</td>
<td>7.38</td>
<td>5.24</td>
<td>7.02</td>
</tr>
<tr>
<td>8</td>
<td>67</td>
<td>0.51</td>
<td>1.20</td>
<td>7.27</td>
<td>4.18</td>
<td>13.17</td>
</tr>
<tr>
<td>9</td>
<td>74</td>
<td>0.61</td>
<td>1.11</td>
<td>7.32</td>
<td>5.59</td>
<td>10.78</td>
</tr>
<tr>
<td>10</td>
<td>70</td>
<td>0.73</td>
<td>2.23</td>
<td>7.32</td>
<td>5.13</td>
<td>8.05</td>
</tr>
<tr>
<td>11</td>
<td>62</td>
<td>0.63</td>
<td>1.26</td>
<td>7.29</td>
<td>3.78</td>
<td>9.11</td>
</tr>
<tr>
<td>12</td>
<td>62</td>
<td>0.56</td>
<td>1.43</td>
<td>7.32</td>
<td>5.94</td>
<td>9.00</td>
</tr>
</tbody>
</table>

Mean (SD) 0.59 (0.13) 1.44 (0.34) 7.32 (0.03) 5.10 (1.12) 9.28 (1.97)

PATIENTS

Twelve patients (11 men, one woman) of median (range) age 69 (49–76) years were studied. Physiological data on admission are shown in table 1. All were judged to have acute exacerbations of COPD on clinical grounds, without focal consolidation on chest radiography, and showed deterioration in spirometry and arterial blood gases. Seven patients had used NIPPV during previous admissions and two patients were established on domiciliary NIPPV. All patients entered the study within 16 hours of admission after a period of initial assessment and therapy during which controlled oxygen therapy (2 l/min) and other
appropriate treatments were instituted. Oxygen therapy was continued for the duration of the study. Four patients were already established on intravenous doxapram at the start of the study, which was continued unchanged. All patients were treated with antibiotics, corticosteroids, and nebulised bronchodilators.

**STUDY DESIGN**

Baseline arterial blood gases were obtained from a radial artery catheter with patients breathing room air and oxygen. Each patient subsequently underwent four periods of nasal ventilation for one hour in randomised order: (a) pressure support 18 cm H₂O; (b) pressure support 18 cm H₂O plus positive end expiratory pressure (PEEP) 6 cm H₂O (IPAP + EPAP); (c) continuous positive airway pressure (CPAP) 8 cm H₂O; and (d) volume cycled NIPPV (BromptonPAC). Modes (a), (b), and (c) were performed with the BiPAP nasal ventilator (S setting), and in mode (d) the BromptonPAC ventilator was used. The EPAP settings were selected to correspond to the levels of intrinsic PEEP noted in similar patients in previous studies. All periods of ventilation were accomplished with the patient in a semi-recumbent position and were supervised to ensure patient-ventilator synchrony and effective triggering of ventilation. Arterial blood gas tensions were obtained immediately before each period of ventilation and at one hour. Owing to the poor clinical condition of these patients it was not technically possible to obtain data by more invasive methods. A minimum of one hour elapsed between different periods of ventilation, during which time blood gas tissues returned to a stable baseline. At the end of the study all patients were established on the mode of ventilation found to be most effective.

The study protocol was approved by the ethics committee of the Royal Brompton Hospital and informed consent was obtained from all subjects.

**STATISTICAL METHODS**

Data were analysed using the BMDP repeated measures of variance programme (BMDP Statistical Software, Los Angeles, California, USA).

**Results**

Pressure support 18 cm H₂O, CPAP 8 cm H₂O, and volume cycled NIPPV (BromptonPAC) all produced significant improvements in Pao₂ (table 2). Repeated measures analysis of variance showed no difference between these three modes. The change in Pao₂ with IPAP + EPAP did not reach statistical significance and three patients experienced great difficulty in tolerating this mode. The order of study periods did not affect outcome.

None of the ventilator modes produced significant improvements in group mean Paco₂. However, the change in Paco₂ varied with the starting Paco₂. The changes in Paco₂ for each

---

**Table 2** Mean changes (kPa) in arterial blood gases + 95% confidence intervals for each ventilator mode studied

<table>
<thead>
<tr>
<th>Pressure support</th>
<th>Paco₂</th>
<th>95% CI</th>
<th>Paco₂</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pressure support</td>
<td>+2.50</td>
<td>1.06 to 3.95</td>
<td>-0.29</td>
<td>-0.59 to +0.01</td>
</tr>
<tr>
<td>IPAP + EPAP</td>
<td>+0.82</td>
<td>-0.07 to +0.23</td>
<td>-0.24</td>
<td>-1.02 to +0.54</td>
</tr>
<tr>
<td>CPAP</td>
<td>+1.35</td>
<td>0.10 to 2.79</td>
<td>+0.54</td>
<td>-0.18 to +0.68</td>
</tr>
<tr>
<td>BromptonPAC</td>
<td>+2.34</td>
<td>1.34 to 3.38</td>
<td>+0.04</td>
<td>-0.41 to +0.60</td>
</tr>
</tbody>
</table>

IPAP, EPAP = inspiratory and expiratory positive airway pressures; CPAP = continuous positive airway pressure.

---

*Individual (→) and mean (—) changes in Paco₂ for all patients (n = 12) achieved using each ventilator mode.*
ventilator mode are shown in the figure. When patients were divided into two groups above or below the median baseline PaCO₂ and this was incorporated into the analysis of variance, it was found that patients with higher initial PaCO₂ levels tended to rise further, while those with lower starting levels tended to fall with treatment. This interaction was significant with a probability value of $p<0.02$. For individual patients this response was consistent for each mode of ventilation; all of the four patients on doxapram infusions at the start of the study showed this pattern of response. No patient required formal mechanical ventilation. The 10 patients who were not on domiciliary ventilation used NIPPV for a median of six days (range 2–13). Mean PaO₂ at discharge was 6–90 (1–01) kPa, PaCO₂ 7–53 (0–81) kPa, median hospital stay 11 days (range 5–22). Five patients died during further acute exacerbations within six months of the study.

**Discussion**

This is the first study to compare the effect of different modes of nasal ventilation in patients with acute exacerbations of COPD. In this group of patients pressure cycled NIPPV, volume cycled NIPPV, and CPAP can bring about significant improvements in oxygenation, although the effect on PaCO₂ is more variable. The addition of positive end expiratory pressure in the form of EPAP was poorly tolerated and produced no additional benefit.

PaO₂ rose consistently with the addition of nasal ventilation whereas, although PaCO₂ tended to fall in patients with lower starting arterial carbon dioxide tensions, in those with the highest initial levels of PaCO₂, there was a further rise. A recent report of CPAP in patients with acute COPD showed a similar pattern of response. Positive end expiratory pressure causes a rise in functional residual capacity (FRC) and consequent increase in airway calibre, preventing small airway closure and improving ventilation-perfusion relationships within the lungs. However, studies in normal subjects and in patients with acute respiratory failure have demonstrated that minute ventilation may fall with the application of CPAP due mainly to a reduced respiratory rate without changes in inspiratory flow rate.

In this study the most severely hypercapnic patients – most of whom required doxapram infusions to maintain or augment respiratory drive – showed a rise in PaCO₂ with the addition of nasal ventilation. NIPPV increased minute ventilation, mainly through an enhanced tidal volume. During acute exacerbations of COPD airway resistance is high and compliance of the ventilatory system is low. In severely affected patients the ventilators used to deliver NIPPV may not be capable of generating sufficiently high pressures to increase minute ventilation enough to bring about a fall in PaCO₂, although there may be other important effects on ventilation-perfusion matching and breathing pattern. The increase in PaO₂ with nasal ventilation further compromised respiratory drive and the patients’ active contribution to ventilation, imposing a greater degree of the workload on to the ventilator.

Leakage from around the nasal mask and mouth is common with NIPPV, particularly in acutely ill patients unfamiliar with the technique. During the study several patients experienced great difficulty in maintaining an adequate seal at the mouth, particularly when using the IPAP + EPAP mode. These patients were unable to adjust to the constant flow through the nasal mask and developed persistent leakage. We believe that this is a major factor accounting for the relative inefficiency of this particular mode of ventilation.

This study confirms that nasal ventilation is effective in improving arterial oxygen tensions. Although PaCO₂ may be controlled in most patients, in those with severe hypercapnia and impaired respiratory drive PaCO₂ may rise further with the initiation of NIPPV.

Nasal ventilation may be of particular use in those patients not considered suitable for tracheal intubation. It is important that this technique is used as an adjunct to maximal conventional therapy, and not as a substitute for intubation and formal mechanical ventilation if required on clinical grounds.

D J Meecham Jones is the British Lung Foundation Robert Luft Fellow.

Nasal ventilation in acute exacerbations of chronic obstructive pulmonary disease: effect of ventilator mode on arterial blood gas tensions.

D J Meecham Jones, E A Paul, C Grahame-Clarke and J A Wedzicha

Thorax 1994 49: 1222-1224
doi: 10.1136/thx.49.12.1222